全文获取类型
收费全文 | 609篇 |
免费 | 37篇 |
专业分类
儿科学 | 229篇 |
妇产科学 | 48篇 |
基础医学 | 13篇 |
口腔科学 | 13篇 |
临床医学 | 42篇 |
内科学 | 167篇 |
神经病学 | 16篇 |
特种医学 | 8篇 |
外科学 | 35篇 |
综合类 | 15篇 |
预防医学 | 25篇 |
药学 | 9篇 |
肿瘤学 | 26篇 |
出版年
2024年 | 2篇 |
2023年 | 4篇 |
2018年 | 9篇 |
2017年 | 17篇 |
2016年 | 15篇 |
2015年 | 19篇 |
2014年 | 28篇 |
2013年 | 22篇 |
2012年 | 56篇 |
2011年 | 33篇 |
2010年 | 8篇 |
2009年 | 8篇 |
2008年 | 59篇 |
2007年 | 29篇 |
2006年 | 29篇 |
2005年 | 46篇 |
2004年 | 45篇 |
2003年 | 36篇 |
2002年 | 37篇 |
2001年 | 18篇 |
2000年 | 6篇 |
1999年 | 7篇 |
1998年 | 8篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 4篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 3篇 |
1990年 | 4篇 |
1989年 | 10篇 |
1988年 | 9篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 5篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1981年 | 4篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1977年 | 3篇 |
1974年 | 3篇 |
1971年 | 1篇 |
1970年 | 1篇 |
1969年 | 1篇 |
1968年 | 1篇 |
1965年 | 1篇 |
1964年 | 1篇 |
1960年 | 1篇 |
排序方式: 共有646条查询结果,搜索用时 15 毫秒
1.
骨髓输液在PICU的应用探讨 总被引:7,自引:0,他引:7
目的 探讨骨髓输液在PICU的适应证、方法及临床效果。方法 选择PICU危重症建立静脉通道困难患儿 30例 ,采用 7号骨穿针或 7~ 9号头皮针于胫骨粗隆下 1~ 2cm穿刺、固定 ,接入医嘱液体 ,记录穿刺所需时间、入液速度及生命体征变化、并发症等。结果 2 8例 1次成功 ,2例用头皮针者有堵塞 ,换针后重新穿刺成功 ,穿刺、固定到接入液体平均时间 (30± 10 )s。速率 :一般压力 (8± 3)ml (kg体重·h) ,加压下 (17± 6 )ml (kg体重·h) ,所有病例均达到了医嘱要求。骨髓输液持续时间 3~ 2 2h ,无 1例出现并发症。结论 骨髓输液在PICU危重症抢救中可迅速建立液体通道 ,争取抢救时间。头皮针比骨髓穿刺针易于固定 ,使用更方便 相似文献
2.
3.
Fatal shoulder dystocia: a review of 56 cases reported to the Confidential Enquiry into Stillbirths and Deaths in Infancy 总被引:1,自引:0,他引:1
Peter Hope Paediatrician Sue Breslin Senior Midwife Linda Lamont Lay Member of CESD † Alexandra Lucas Community Midwife †† Denis Martin Obstetrician ‡ Isabella Moore Paediatric Pathologist ‡‡ James Pearson Reader § Dawn Saunders Midwife §§ Ralph Settatree Obstetrician & Director CESD §§ 《BJOG : an international journal of obstetrics and gynaecology》1998,105(12):1256-1261
Objective To use information collected by the Confidential Enquiry into Stillbirths and Deaths in Infancy to help obstetric, midwifery and paediatric practice in the management of shoulder dystocia.
Design Review of casenotes by a multidisciplinary focus group.
Sample All 56 cases reported to the Confidential Enquiry into Stillbirths and Deaths in Infancy from England, Wales and Northern Ireland in 1994 and 1995, where stillbirth or neonatal death was attributed to shoulder dystocia.
Main outcome measures Case notes were reviewed with respect to a range of perinatal variables. Comparisons were made with normative data from other studies when appropriate.
Results Maternal obesity and big babies were over-represented in pregnancies complicated by fatal shoulder dystocia. Fetal compromise was recorded in 26% of labours. The median time interval between delivery of the head and the rest of the body was only five minutes. The lead professional at the time the head was delivered was a midwife in 65% of cases. Middle grade or senior obstetric staff were supervising 47% of cases by the time the body was delivered.
Conclusions Antenatal prediction of shoulder dystocia is imprecise, and the majority of deliveries are attended by midwives. A relatively brief delay in delivery of the shoulders may be associated with a fatal outcome. 相似文献
Design Review of casenotes by a multidisciplinary focus group.
Sample All 56 cases reported to the Confidential Enquiry into Stillbirths and Deaths in Infancy from England, Wales and Northern Ireland in 1994 and 1995, where stillbirth or neonatal death was attributed to shoulder dystocia.
Main outcome measures Case notes were reviewed with respect to a range of perinatal variables. Comparisons were made with normative data from other studies when appropriate.
Results Maternal obesity and big babies were over-represented in pregnancies complicated by fatal shoulder dystocia. Fetal compromise was recorded in 26% of labours. The median time interval between delivery of the head and the rest of the body was only five minutes. The lead professional at the time the head was delivered was a midwife in 65% of cases. Middle grade or senior obstetric staff were supervising 47% of cases by the time the body was delivered.
Conclusions Antenatal prediction of shoulder dystocia is imprecise, and the majority of deliveries are attended by midwives. A relatively brief delay in delivery of the shoulders may be associated with a fatal outcome. 相似文献
4.
1426例幽门螺杆菌抗体检测的临床价值探讨 总被引:2,自引:0,他引:2
李鑫 《安徽卫生职业技术学院学报》2004,3(3):15-16
目的:探讨I型和II型幽门螺杆菌(Helicobacter Pylori,简称 HP)与小儿腹痛的关系.方法:对1426例腹痛患儿,用免疫印迹法进行分型检测.结果:检出HP阳性590例,占41.37%;其中I型HP感染342例,占57.97%;II型248例,占42.03%.结论:免疫印迹法分型检测HP对临床诊治具有重要的指导意义. 相似文献
5.
Kurt Schmidlin Adrian Spoerri Felix Niggli Michael Grotzer Nicolas X. von der Weid Matthias Egger Nicole Probst‐Hensch Marcel Zwahlen Claudia E. Kuehni and the Swiss Paediatric Oncology Group the Swiss National Cohort Study 《International journal of cancer. Journal international du cancer》2016,138(12):2856-2866
In this study, we investigated whether childhood cancer survival in Switzerland is influenced by socioeconomic status (SES), and if disparities vary by type of cancer and definition of SES (parental education, living condition, area‐based SES). Using Cox proportional hazards models, we analyzed 5‐year cumulative mortality in all patients registered in the Swiss Childhood Cancer Registry diagnosed 1991–2006 below 16 years. Information on SES was extracted from the Swiss census by probabilistic record linkage. The study included 1602 children (33% with leukemia, 20% with lymphoma, 22% with central nervous system (CNS) tumors); with an overall 5‐year survival of 77% (95%CI 75–79%). Higher SES, particularly parents' education, was associated with a lower 5‐year cumulative mortality. Results varied by type of cancer with no association for leukemia and particularly strong effects for CNS tumor patients, where mortality hazard ratios for the different SES indicators, comparing the highest with the lowest group, ranged from 0.48 (95%CI: 0.28–0.81) to 0.71 (95%CI: 0.44–1.15). We conclude that even in Switzerland with a high quality health care system and mandatory health insurance, socioeconomic differences in childhood cancer survival persist. Factors causing these survival differences have to be further explored, to facilitate universal access to optimal treatment and finally eliminate social inequalities in childhood cancer survival. 相似文献
6.
Morten Tulstrup Thomas L. Frandsen Jonas Abrahamsson Bendik Lund Kim Vettenranta Olafur Gisli Jonsson Hanne Vibeke Hansen Marquart Birgitte Klug Albertsen Mats Heyman Kjeld Schmiegelow On behalf of the Nordic Society of Paediatric Haematology Oncology 《European journal of haematology》2018,100(1):53-60
Objectives
This randomized controlled trial tested the hypothesis that children with non‐high‐risk acute lymphoblastic leukemia could benefit from individualized 6‐mercaptopurine increments during consolidation therapy (NCT00816049). Primary and secondary end points were end of consolidation minimal residual disease (MRD) positivity and event‐free survival.Methods
392 patients were randomized to experimental and 396 to standard therapy. Patients allocated to standard therapy received oral 6‐mercaptopurine (25 mg/m2/day) from days 30 to 85, while the experimental arm received stepwise increments of additional 25 mg/m2/day beginning on days 50 and/or 71 unless dose‐limiting myelosuppression had occurred.Results
In the experimental arm, 166 patients (42%) received one dose increment, and 62 (16%) received two. Fifty‐seven of 387 (15%) patients in the experimental arm were MRD positive at end of consolidation vs 77 of 389 (20%) in the control arm (P = .08). Five‐year probability of event‐free survival was 0.89 (95% CI: 0.85‐0.93) in the experimental arm vs 0.93 (0.90‐0.96) in the control arm (P = .13). The median accumulated length of 6‐mercaptopurine treatment interruptions was 7 (IQR 2‐12) in the experimental arm vs 4 (IQR 0‐10) in the control arm (P = .002).Conclusion
This study found no benefit from individualized 6‐mercaptopurine increments compared to standard therapy. 相似文献7.
Sam T Ernest TB Walsh J Williams JL;on behalf of the European Paediatric Formulation Initiative 《International journal of pharmaceutics》2012,435(2):115-123
The design and selection of new pharmaceutical dosage forms involves the careful consideration and balancing of a quality target product profile against technical challenges and development feasibility. Paediatric dosage forms present particular complexity due to the diverse patient population, patient compliance challenges and safety considerations of this vulnerable population. This paper presents a structured framework for assessing the comparative benefits and risks of different pharmaceutical design options against pre-determined criteria relating to (1) efficacy, (2) safety and (3) patient access. This benefit/risk framework has then been applied to three hypothetical, but realistic, scenarios for paediatric dosage forms in order to explore its utility in guiding dosage form design and formulation selection. The approach allows a rigorous, systematic and qualitative assessment of the merits and disadvantages of each dosage form option and helps identify mitigating strategies to modify risk. The application of a weighting and scoring system to the criteria depending on the specific case could further refine the analysis and aid decision-making. In this paper, one case study is scored for illustrative purposes. However, it is acknowledged that in real development scenarios, the generation of actual data considering the very specific situation for the patient/product/developer would come into play to drive decisions on the most appropriate dosage form strategy. 相似文献
8.
9.
Estimation of the false-negative rate in newborn screening for congenital adrenal hyperplasia 总被引:2,自引:0,他引:2
Votava F Török D Kovács J Möslinger D Baumgartner-Parzer SM Sólyom J Pribilincová Z Battelino T Lebl J Frisch H Waldhauser F;Middle European Society for Paediatric Endocrinology -- Congenital Adrenal Hyperplasia 《European journal of endocrinology / European Federation of Endocrine Societies》2005,152(6):869-874
OBJECTIVE: Newborn screening based on measurement of 17alpha-hydroxyprogesterone (17-OHP) in a dried blood spot on filter paper is an effective tool for early diagnosis of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Its most important rationale is prevention of a life-threatening salt-wasting (SW) crisis; in moderate forms of CAH, early diagnosis and treatment may prevent permanent negative effects of androgen overproduction. Our target was to analyse if all CAH patients who had been identified clinically before puberty would have been detected by the newborn screening. METHODS: Newborn screening cards of 110 CAH patients born between 1988 and 2000 in five Middle-European countries and diagnosed prior to puberty (77 SW and 33 moderate) and cards from 920 random, healthy newborn controls were analysed. CAH screening had not yet been introduced during this time. The diagnosis was based on clinical and laboratory signs and, in most cases, on CYP21 gene mutation analysis. All 17-OHP measurements in dried blood spots were carried out using a time-resolved fluoroimmunoassay kit. RESULTS: In the newborn screening blood spots, the median of 17-OHP levels was 561 nmol/l (range 91-1404 nmol/l) in subjects with the SW form and 40 nmol/l (4-247 nmol/l) in the moderate form. All 77 SW patients would have been detected by newborn screening using the recommended cut-off limits (30 nmol/l). However, 10 of 33 patients with moderate CAH would have been missed. 17-OHP levels of all controls were below the cut-off. CONCLUSION: Newborn screening is efficient for diagnosing the SW form of CAH, but is inappropriate for identifying all patients with a moderate form of CAH. It appears that the false-negative rate is at least one-third in children with the moderate form of CAH. 相似文献
10.
Permanent diabetes mellitus in the first year of life 总被引:5,自引:0,他引:5
Iafusco D Stazi MA Cotichini R Cotellessa M Martinucci ME Mazzella M Cherubini V Barbetti F Martinetti M Cerutti F Prisco F;Early Onset Diabetes Study Group of the Italian Society of Paediatric Endocrinology Diabetology 《Diabetologia》2002,45(6):798-804
AIMS/HYPOTHESIS: The pathogenesis of permanent diabetes mellitus diagnosed early in life is heterogeneous and, in most cases, not known. We aimed at identifying markers differentiating between non-autoimmune and autoimmune diabetes. METHODS: The clinical, genetic and epidemiological features of 111 diabetic patients (62 males) who received insulin within 12 months of life were studied. RESULTS: The epidemic curve by age of diabetes onset revealed two subsets of patients at a cutoff of 180 days. In the group with diabetes onset before 180 days ("early onset" permanent diabetes) the analysis of HLA susceptibility heterodimers (available for 21 individuals) showed that 76% had a "protective" HLA genotype for Type I (insulin-dependent) diabetes mellitus as compared to 11.9% (5/42) of the later onset group. Accordingly, "early onset" children were less likely to have autoimmunity markers (4 out of 26 tested) than children with onset after 180 days (13 out 20 tested) (15.4% vs. 65.0%, p<0.01). Of note, 19 out of 20 (or the 95%) patients who were born on the island of Sardinia, an Italian region where the incidence of Type I diabetes is six times higher than continental Italy (33/100,000/year vs 5/100,000/year), were included in the later onset group (>180 days). Small-for-date birthweight, a possible sign of reduced foetal insulin secretion, was more common in the "early onset" group (OR=9.9, 95%-CI 2.6-38.6). CONCLUSION/INTERPRETATION: These results, obtained in the largest population-based cohort of diabetic infants hitherto reported, suggest that "early onset" permanent diabetes cases differ from later onset cases and that most of them do not have an autoimmune pathogenesis. 相似文献